53P - Impact of chronic hepatitis virus infection on the feasibility and efficacy for Asian patients with hepatocellular carcinoma in Phase I clinical tr...

Date 05 March 2018
Event TAT 2018 - Targeted Anticancer Therapies
Session Selected poster presentations
Topics Hepatobiliary Cancers
Cancer in Special Situations
Presenter Takafumi Koyama
Citation Annals of Oncology (2018) 29 (suppl_3): iii10-iii34. 10.1093/annonc/mdy047
Authors T. Koyama1, S. Kondo2, T. Shimizu2, Y. Fujiwara1, S. Kitano3, T. Ebata1, A. Shimomura2, C. Morizane4, T. Okusaka4, N. Yamamoto2
  • 1Department Of Experimental Therapeutics, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 3Experimental Therapeutics, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 4Department Of Hepatobiliary And Pancreatic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP

Abstract

In Asia, chronic hepatitis B and C virus infections (CHVI) are major risk factors for liver fibrosis and hepatocellular carcinoma (HCC). Patients with advanced HCC have limited effective therapeutic options and are potential candidates for early phase clinical trials for new anti-cancer agents. The impact of CHVI on the feasibility and efficacy for patients with HCC in Phase I trials (P-Is) has not been reported or elucidated in Western countries.